Heinzer H, Huland E, Huland H
Department of Urology, University Clinic Eppendorf, Martinistrasse 52, University of Hamberg, 20246 Hamburg, Germany.
World J Urol. 2001 Apr;19(2):111-9. doi: 10.1007/s003450000191.
We review the current literature on systemic therapy for patients with metastatic renal cell carcinoma. Metastatic renal cell carcinoma remains highly resistant to chemotherapy and hormonal agents not justifying its use as a single agent. Interleukin-2 immunotherapy is the most effective treatment for metastatic renal cell carcinoma available today. There is evidence that interleukin-2 improves survival and yields long-lasting remissions in selected patients; the optimal dose and schedule still need to be defined. Response rates in patients treated with subcutaneous interleukin-2 are similar to those achieved with high-dose bolus intravenous applications. Questions remain concerning quality of life and benefit-to-risk ratio with respect to immunotherapy in individual patients. Different routes of administration of interleukin-2 such as local application, promise to improve quality of life and survival times.
我们回顾了目前关于转移性肾细胞癌患者全身治疗的文献。转移性肾细胞癌对化疗和激素药物仍具有高度抗性，因此不适合将其作为单一药物使用。白细胞介素-2免疫疗法是目前可用于转移性肾细胞癌的最有效治疗方法。有证据表明，白细胞介素-2可提高特定患者的生存率并产生持久缓解；最佳剂量和给药方案仍有待确定。皮下注射白细胞介素-2治疗的患者的缓解率与大剂量静脉推注应用所达到的缓解率相似。关于个体患者免疫治疗的生活质量和风险效益比仍存在问题。白细胞介素-2的不同给药途径，如局部应用，有望改善生活质量和延长生存时间。
Zotero 插件